Skip to main content
Log in

3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway

  • Original Paper
  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is one of the main causes of death in cancer. Some naphthalimide derivatives exert high anti-proliferative effects on HCC. In this study, it is confirmed that 3-nitro-naphthalimide and nitrogen mustard conjugate (NNM-25), a novel compound conjugated by NNM-25, displayed more potent therapeutic action on HCC, both in vivo and in vitro, than amonafide, a naphthalimide drug in clinical trials. More importantly, preliminary toxicological evaluation also supported that NNM-25 exhibited less systemic toxicity than amonafide at the therapeutic dose. The antitumor mechanism of conjugates of naphthalimides with nitrogen mustard remains poorly understood up to now. Here, we first reported that apoptosis might be the terminal fate of cancer cells treated with NNM-25. Inhibition of p53 by siRNA resulted in a significant decrease of NNM-25-induced apoptosis, which corroborated that p53 played a vital role in the cell apoptosis triggered by NNM-25. NNM-25 inhibited the PARP-1 activity, AKT phosphorylation, up-regulated the protein expression of p53, Bad, and mTOR as well as down-regulating the protein expression of Bcl-2 and decreasing mitochondrial membrane potential. It also facilitated cytochrome c release from mitochondria to cytoplasm, activated caspase 8, caspase 9, and caspase 3 in HepG2 cells in vitro, as also authenticated in H22 tumor-bearing mice in vivo. Collectively, the conjugation of naphthalimides with nitrogen mustard provides favorable biological activity and thus is a valuable strategy for future drug design in HCC therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Alves RC, Alves D, Guz B, Matos C, Viana M, Harriz M (2011) Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 10:21–27

    PubMed  Google Scholar 

  2. Duffy A, Greten T (2010) Developing better treatments in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 4:551–560

    Article  PubMed  Google Scholar 

  3. Ingrassia L, Lefranc F, Kiss R, Mijatovic T (2010) Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem 16:1192–1213

    Article  Google Scholar 

  4. Tian ZY, Xie SQ, Du YW, Ma YF, Zhao J, Gao WY, Wang CJ (2009) Synthesis, cytotoxicity and apoptosis of naphthalimide polyamine conjugates as antitumor agents. Eur J Med Chem 44:393–399

    Article  PubMed  CAS  Google Scholar 

  5. Tian ZY, Xie SQ, Mei ZH, Zhao J, Gao WY, Wang CJ (2010) Conjugation of substituted naphthalimides to polyamines as cytotoxic agents targeting the Akt/mTOR signal pathway. Org Biomol Chem 7:4651–4660

    Article  Google Scholar 

  6. Pain A, Samanta S, Dutta S, Saxena AK, Shanmugavel M, Kampasi H, Quazi GN, Sanyal U (2003) Synthesis and evaluation of substituted naphthalimide nitrogen mustards as rationally designed anticancer compounds. Acta Pol Pharm 60:285–291

    PubMed  CAS  Google Scholar 

  7. Horton JK, Stefanick DF, Zeng JY, Carrozza MJ, Wilson SH (2011) Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibitory. DNA Repair 10:225–234

    Article  PubMed  CAS  Google Scholar 

  8. Powell C, Mikropoulos C, Kaye SB, Nutting CM, Bhide SA, Newbold K (2010) Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 36:566–575

    Article  PubMed  CAS  Google Scholar 

  9. Rodon J, Iniesta MD, Papadopoulos K (2009) Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 18:31–43

    Article  PubMed  CAS  Google Scholar 

  10. Heacock ML, Stefanick DF, Horton JK, Wilson SH (2010) Alkylation DNA damage in combination with PARP inhibitory results in formation of S-phase-dependent double-strand breaks. DNA Repair 9:929–936

    Article  PubMed  CAS  Google Scholar 

  11. Wang S, Jia L, Zhou H, Shi W, Zhang J (2009) Knockdown of caveolin-1 by siRNA inhibits the transformation of mouse hepatoma H22 cells in vitro and in vivo. Oligonucleotides 19:81–88

    Article  PubMed  Google Scholar 

  12. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L (2010) Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51:154–164

    Article  PubMed  CAS  Google Scholar 

  13. Xie SQ, Li Q, Zhang YH, Wang JH, Mei ZH, Zhao J, Wang CJ (2011) NPC-16, a novel naphthalimide-polyamine conjugate, induced apoptosis and autophagy in human hepatoma HepG2 cells and Bel-7402 cells. Apoptosis 16:27–34

    Article  PubMed  CAS  Google Scholar 

  14. Alano CC, Kauppinen TM, Valls AV, Swanson RA (2006) Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 103:9685–9690

    Article  PubMed  CAS  Google Scholar 

  15. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387–402

    Article  PubMed  CAS  Google Scholar 

  16. Van Quaquebeke E, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, El Yazidi M, Van Vynckt F, Mijatovic T, Lefranc F, Darro F, Kiss R (2007) 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl}carbamoyl)acetamide (UNBS3157), a novel non-hematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem 50:4122–4134

    Article  PubMed  Google Scholar 

  17. Pain A, Samanta S, Dutta S, Saxena AK, Shanmugavel M, Kampasi H (2003) Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent. J Exp Clin Cancer Res 22:411–418

    PubMed  CAS  Google Scholar 

  18. Sandhu SK, Yap TA, de Bono JS (2010) Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 46:9–20

    Article  PubMed  CAS  Google Scholar 

  19. Löser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA (2010) Chalmers, sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 9:1775–1787

    Google Scholar 

  20. Huang SH, Xiong M, Chen XP, Xiao ZY, Zhao YF, Huang ZY (2008) PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells. Oncol Rep 20:567–572

    PubMed  CAS  Google Scholar 

  21. Fiorillo C, Ponziani V, Giannini L, Cecchi C, Celli A, Nassi N, Lanzilao L, Caporale R, Nassi P (2006) Protective effects of the PARP-1 inhibitor PJ34 in hypoxic-reoxygenated cardiomyoblasts. Cell Mol Life Sci 63:3061–3071

    Article  PubMed  CAS  Google Scholar 

  22. Pu T, Zhang XP, Liu F, Wang W (2010) Coordination of the nuclear and cytoplasmic activities of p53 in response to DNA damage. Biophys J 99:1696–1705

    Article  PubMed  CAS  Google Scholar 

  23. Smith ML, Kumar MA (2010) The “two faces” of tumor suppressor p53-revisited. Mol Cell Pharmacol 2:117–119

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was funded by the National Natural Science Foundation of China (No. 90913001) for Chao-jie Wang, Projects of Science and Technology of Henan (No. 0821022700; 102300410095) and China Postdoctoral Science Foundation Funded Project (No. 20090450092; 201003395) for Song-qiang Xie.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chao-jie Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xie, Sq., Zhang, Yh., Li, Q. et al. 3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway. Apoptosis 17, 725–734 (2012). https://doi.org/10.1007/s10495-012-0712-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-012-0712-7

Keywords

Navigation